101,886 research outputs found
Chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma
No full textPredictive value of serum Chromogranin A (CgA) in clinical understaging of patients with prostate adenocarcinoma submitted to radical prostatectomy (RRP)
No full text
Benign prostatic hyperplasia: What about a campaign for prevention?
No full textObjectives: In an era when prevention is considered better than cure, is there a rationale for benign prostatic hyperplasia (BPH) prevention? Materials and Methods: Medline and Current Content databases were searched for studies conduced in the last 10 years on BPH and the feasibility of prevention program. Results: Some important criteria for promoting prevention can be found in BPH disease. The significant impact of BPH on the male population and on its quality of life is well established. Knowledge of the etiopathogenesis of this disease is rapidly improving. However, the use of PSA or othe rmarkers to select a population at higher risk for developing BPH and its clinical manifestations needs to be better established. More data are available for secondary prevention against BPH progression. Although the action of some natural and nutritional agents on BPH tissue has been demonstrated experimentally, data from prospe tive clinical trials are not available. Synthetic agents such as 5alpha-reductase inhibitors or COX-2 inhibitors may be effective, but clinical results for primary prevention of BPH have not been reported. Conclusion: At present, we propose a BPH prevention program as a basis for discussion and future work
Role of radical retropubic prostatectomy in patients with locally advanced prostate cancer: The influence of Gleason score 8-10
No full textBackground: To define whether in locally advanced prostate cancer submitted to radical retropubic prostatectomy (RRP) the presence of a Gleason score 8-10 represents an index of high risk for progression and cancer-specific death. Methods: Finally, a total of 130 men with pathologically confirmed T3 cancer were included in this analysis. On the basis of the histological grade obtained at RRP, patients were divided into two groups: patients with a Gleason score 8-10 (group 1) and patients with a Gleason score <8 (group 2). Postoperative follow-up ranged from 24 to 120 months (median 60). After RRP no patients received additional treatments until a biochemical or clinical disease progression was found. Kaplan-Meier projections were used in each group. Results: After RRP, 41 patients (31.5%) had a Gleason score 8-10 tumor. The incidence of positive lymph nodes was significantly higher (p = 0.0030) in group 1 (36.6%) when compared with group 2 (12.3%). Significant differences between the two groups were also found with respect to seminal vesicle involvement (p = 0.0045) and positive surgical margins (p = 0.0040). The actuarial cumulative disease-specific survival for group 1 and group 2 was, respectively, 69 and 82% at 10 years. A Kaplan-Meier analysis demonstrated a 100% disease-specific survival, a 92% clinical progression-free survival and a 38% biochemical progression-free survival 10 years postoperatively if patients in group 1 had negative surgical margins and negative lymph nodes (48.8%). Conclusions: Our data indicate a significant association between Gleason score 8-10 and disease-specific survival, only if patients in group 1 are stratified on the basis of surgical margins and/or lymph node involvement. Copyright (C) 2003 S. Karger AG, Basel
Effect of non-steroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma
No full textEffects of intermittent versus continuous androgen deprivation therapy on neuroendocrine differentiation in prostate cancer
No full textEffetti della monoterapia antiandrogena vs castrazione sulla differenziazione neuroendocrina del carcinoma della prostata
No full textA combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and reduces chromograni A (CgA) levels in androgen ablation - refractory prostate cancer patients
No full textValore predittivo della cromogranina A nella sottostadiazione clinica dei pazienti con adenocarcinoma prostatico sottoposti a prostatectomia radicale.
No full text- …
